NCT02474537View on ClinicalTrials.gov

INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

June 12, 2015

Primary Completion Date

August 14, 2017

Study Completion Date

September 12, 2017

Conditions
Hepatic Impairment
Interventions
DRUG

INC280

Single 200 mg dose INC280

Trial Locations (5)

27710

Duke University Medical Center Oncology, Durham

32086

Orlando Clinical Research Center, Orlando

33136

University of Miami Miller School of Medicine Clinical Resea Oncology, Miami

33142

Clinical Pharmacology of Miami, LLC., Miami

55404

DaVita Clinical Research, Minneapolis

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY